香港联交所最新资料显示，2月20日，汇聚科技(01729)股东将股票存入花旗银行，存仓市值17.85亿港 元，占比5.45%。 汇聚科技公告，配售协议所载的所有条件已获达成，配售事项已于2026年2月20日根据配售协议的条款 及条件完成。合共1.08亿股配售股份(占紧接配售事项完成前本公司现有已发行股本约5.45%，及紧随配 售事项完成后经配发及发行配售股份扩大后的本公司已发行股本约5.16%)已成功配售予不少于六名承配 人，配售价为每股15.22港元。 ...

Core Viewpoint - OKURA HOLDINGS (01655) has completed a placement of 84.98 million shares at a price of HKD 0.143 per share, raising approximately HKD 10.38 million for various operational purposes [1] Group 1: Shareholder Activity - On February 13, shareholders of OKURA HOLDINGS deposited shares into 盈立证券, with a market value of HKD 18.8656 million, representing 13.38% of the total shares [1] Group 2: Fundraising and Allocation - The company completed the placement of 84.98 million shares on February 13, 2026, at a price of HKD 0.143 per share, netting around HKD 10.38 million [1] - Approximately 50% of the raised funds will be used for purchasing Japanese pachinko machines and Japanese slot machines, while 30% will be allocated for renovating or upgrading existing Japanese pachinko game halls and marketing expenses [1] - The remaining 20% of the funds will be utilized for general operational expenses of the group [1]

Group 1 - The core point of the article is that CMON has successfully completed a share placement agreement, with a total of 10.32 million shares being placed at a price of HKD 0.9500 per share, representing approximately 16.67% of the company's enlarged issued share capital after the placement [1] - The shares were deposited into the Metaverse (International) Securities, with a total market value of HKD 15.48 million, accounting for 20% of the shares [1] - All conditions outlined in the placement agreement have been met, and the placement was completed on February 12, 2026 [1]

Core Viewpoint - Company completed the placement of a total of 69.256 million shares at a price of HKD 12.18 per share, raising approximately HKD 835 million, with 90% allocated for the global Phase III clinical trial preparation of the obesity treatment small molecule oral GLP-1 receptor agonist ASC30 [1] Group 1 - The placement was completed on February 10, 2026 [1] - Approximately 90% of the raised funds will be used for the preparation, groundwork, and initiation of the global Phase III clinical trial for ASC30 [1] - The remaining 10% of the funds is suggested for operational expenses and other general corporate purposes [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」或「香港聯交所」）及香港中 央結算有限公司（「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損 失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 潛在投資者在決定是否投資於發售股份前，應細閱招股章程以了解下文所述有關全球發售的詳 細資料。投資者應僅依賴招股章程所載資料作出有關發售股份的任何投資決定。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區或法律禁 止此類發佈的任何其他司法權區）發佈、刊發或派發。本公告並不構成或組成在美國境內或於 任何其他司法權區購買或認購證券的任何要約或招攬的一部分。本公告所述證券並無亦不會根 據1933年美國證券法（經不時修訂）（「美國證券法」）或美國任何州或其他司法權區的證券法登 記。該等證券不得在美國境內提呈發售、出售、質押或以其他方式轉讓，惟獲豁免遵守美國證 券法登記規定或在毋須遵守登記規定的交易中且依據任何適用美國州證券法進行者則除外 ...

Group 1 - The core viewpoint of the article is that New City Development has raised funds through a share placement to improve liquidity and support future business operations [1] - On February 5, New City Development allocated 198 million shares to 9 institutional investors at a price of HKD 2.39 per share, raising a total of HKD 473 million [1] - The raised funds will primarily be used for future business development and daily operational needs [1]

Group 1 - Tianqi Lithium Industries (002466) experienced a significant drop of over 9% upon resuming trading, with a current price of 44.98 HKD and a trading volume of 74.6883 million HKD [1] - The company announced a plan to place 65.05 million new H-shares and issue zero-coupon convertible bonds totaling 2.6 billion RMB, with expected total proceeds of approximately 5.8591 billion HKD, net proceeds around 5.8306 billion HKD [1] - The funds raised will support the company's strategic development in the lithium sector, including capital expenditures for project development and optimization, acquisition of quality lithium mining assets, and general corporate purposes [1] Group 2 - The company has entered into a revised placement agreement for the new H-shares, with a placement price of 45.05 HKD per share, representing a discount of about 9% compared to the last closing price of 49.5 HKD on February 3, 2026 [1] - The total expected proceeds from the placement of shares is approximately 2.9305 billion HKD, with net proceeds estimated at around 2.924 billion HKD [1] - Additionally, the company will issue zero-coupon convertible bonds with a principal amount of 2.6 billion RMB, with an initial conversion price of 51.85 HKD per H-share, representing a premium of about 4.7% over the last closing price [2] - The total expected proceeds from the bond issuance is approximately 2.9286 billion HKD, with net proceeds estimated at around 2.9066 billion HKD [2]

Group 1 - The company, Brainstorm Cell Therapeutics Inc. (6681.HK), plans to issue 92 million shares through a placement, representing approximately 6.77% of the enlarged share capital [1] - The placement price is set at HKD 5.6 per share, which is a discount of about 12.09% compared to the closing price of HKD 6.37 from the previous day [1] - The total funds raised are expected to be HKD 515 million, with a net amount of approximately HKD 501 million after expenses [1] Group 2 - Approximately 50% of the net proceeds will be allocated to research and development initiatives [1] - About 30% of the funds will be used for domestic and international market development [1] - The remaining 20% will be split between strategic investments and acquisitions (10%) and general corporate operational expenses (10%) [1]

Group 1 - The core point of the article is that STERLING GP (01825) has completed a placement agreement, with shareholders depositing shares into KGI Securities Asia, amounting to a market value of HKD 7.81 million, representing 20% of the total [1] - The placement agreement conditions have been fulfilled, and the completion date is confirmed as January 22, 2026 [1] - A total of 69.12 million shares were placed at a price of HKD 0.10 per share, which corresponds to approximately 16.7% of the company's issued share capital post-placement [1] Group 2 - The net proceeds from the placement, after deducting related expenses, are approximately HKD 6.77 million, equating to a net issue price of about HKD 0.098 per share [1]

Core Viewpoint - 康龙化成 has successfully completed a share placement, raising a net amount of HKD 1.319 billion, which will be allocated for various strategic purposes [1] Group 1: Share Placement Details - 康龙化成 announced that all conditions for the share placement have been met and it will be completed on January 22, 2026 [1] - The placement agent has sold a total of 58.4408 million shares at a price of HKD 22.82 per share to no fewer than six independent subscribers [1] Group 2: Use of Proceeds - Approximately 70% of the net proceeds will be used for project construction to enhance the company's laboratory service facilities, drug process development, and production capacity [1] - About 10% of the funds will be allocated to repay bank loans and other borrowings to optimize the company's capital structure [1] - The remaining 20% will be used to supplement working capital and for other general corporate purposes [1]